379 related articles for article (PubMed ID: 9477948)
41. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.
D'Amico S; Martial JA; Struman I
FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964
[TBL] [Abstract][Full Text] [Related]
42. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
[TBL] [Abstract][Full Text] [Related]
43. Serpin-resistant mutants of human tissue-type plasminogen activator.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF
Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599
[TBL] [Abstract][Full Text] [Related]
44. A model of the reactive form of plasminogen activator inhibitor-1.
Aertgeerts K; De Bondt HL; De Ranter C; Declerck PJ
J Struct Biol; 1994; 113(3):239-45. PubMed ID: 7734247
[TBL] [Abstract][Full Text] [Related]
45. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
[TBL] [Abstract][Full Text] [Related]
46. Hydrocortisone regulates the dynamics of plasminogen activator and plasminogen activator inhibitor expression in cultured murine keratinocytes.
Bator JM; Cohen RL; Chambers DA
Exp Cell Res; 1998 Jul; 242(1):110-9. PubMed ID: 9665808
[TBL] [Abstract][Full Text] [Related]
47. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
J Pharm Belg; 2000; 55(2):57-8. PubMed ID: 10842928
[TBL] [Abstract][Full Text] [Related]
48. Construction, expression and characterization of tissue-type plasminogen activator mutants.
Liu S; Huang P; Huang C
Sci China B; 1995 Nov; 38(11):1341-8. PubMed ID: 8745532
[TBL] [Abstract][Full Text] [Related]
49. Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis.
Novoa de Armas H; Dewilde M; Verbeke K; De Maeyer M; Declerck PJ
Structure; 2007 Sep; 15(9):1105-16. PubMed ID: 17850750
[TBL] [Abstract][Full Text] [Related]
50. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
51. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
van Meijer M; Gebbink RK; Preissner KT; Pannekoek H
FEBS Lett; 1994 Oct; 352(3):342-6. PubMed ID: 7523190
[TBL] [Abstract][Full Text] [Related]
52. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
53. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase.
Urano T; Wu K; Ihara H; Takada Y; Takada A
Pol J Pharmacol; 1996; 48(2):209-13. PubMed ID: 9112653
[TBL] [Abstract][Full Text] [Related]
54. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
55. Regulation of tissue-type plasminogen activator and its inhibitor (PAI-1) by lipopolysaccharide-induced phagocytosis in a Sertoli cell line.
Bourdon V; Defamie N; Fenichel P; Pointis G
Exp Cell Res; 1999 Mar; 247(2):367-72. PubMed ID: 10066364
[TBL] [Abstract][Full Text] [Related]
56. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
[TBL] [Abstract][Full Text] [Related]
57. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator.
Björquist P; Ehnebom J; Inghardt T; Deinum J
Biochim Biophys Acta; 1997 Aug; 1341(1):87-98. PubMed ID: 9300812
[TBL] [Abstract][Full Text] [Related]
58. Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography.
Strömqvist M; Karlsson KE; Björquist P; Andersson JO; Byström M; Hansson L; Johansson T; Deinum J
Biochim Biophys Acta; 1996 Jun; 1295(1):103-9. PubMed ID: 8679667
[TBL] [Abstract][Full Text] [Related]
59. A monoclonal antibody that does not recognize tissue-type plasminogen activator bound to its naturally occurring inhibitor.
Schleef RR; Wagner NV; Sinha M; Loskutoff DJ
Thromb Haemost; 1986 Dec; 56(3):328-32. PubMed ID: 2436333
[TBL] [Abstract][Full Text] [Related]
60. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
